Hims & Hers Health, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 58/100
What the filing says
Hims & Hers reported Q2 2026 revenue of $753.2M (38% YoY), with subscribers reaching 2.9M (19% YoY growth). The company raised full-year 2026 revenue guidance to $3.1–3.3B and Adjusted EBITDA guidance to $275–$325M. However, gross margin contracted from 76% to 64%, net loss widened to $86.3M (vs. $42.5M net income in Q2 2025), and Adjusted EBITDA declined to $60.3M from $82.2M YoY, driven by the Eucalyptus acquisition (closed June 2026, adding ~$123.8M Rest of World revenue), restructuring charges ($38.1M H1 2026 related to US weight-loss strategic shift), and legal contingencies ($62.5M H1 2026).
Why this rating
Strong top-line growth (+38% YoY) and raised FY guidance are positive; however, margin compression, swing to net loss, declining Adjusted EBITDA YoY, substantial non-recurring charges ($62.5M legal, $38.1M restructuring), and negative free cash flow ($68.2M Q2, $15.2M H1) offset growth. Acquisition integration and strategic shift execution risk material relative to $10.1B market cap.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.